---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-006182"
form_type: "8-K"
ticker: "BDX"
cik: "0000010795"
company_name: "BECTON DICKINSON & CO"
filed_at: "2026-02-09T23:59:59+00:00"
generated_at: "2026-05-16T03:48:42.845946+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BD Q1 revenue $5.25B beats; closes Waters deal; affirms FY26 guidance

## Summary
- Revenue $5.252B (+1.6% reported, +0.4% FX neutral); GAAP EPS $1.34, adjusted EPS $2.91.
- BD to close combination of Biosciences & Diagnostic Solutions business with Waters Corporation on Feb 9, 2026.
- Affirms FY26 revenue growth guidance; provides New BD adjusted diluted EPS guidance.
- Announced $110M investment for Neopak syringe production in Nebraska; FDA clearance for EnCor EnCompass biopsy system.
- Adjusted diluted EPS $2.91, down 15.2% YoY on reported basis but beat expectations.

## SEC filing metadata
- accession: 0001628280-26-006182
- form_type: 8-K
- ticker: BDX
- cik: 0000010795
- company_name: BECTON DICKINSON & CO
- filed_at: 2026-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10795/000162828026006182/0001628280-26-006182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10795/000162828026006182/bdx-20260209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-006182
- JSON: https://secwatch.observer/filing/0001628280-26-006182.json
- Plain text: https://secwatch.observer/filing/0001628280-26-006182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.